Edison Investment Research - Pharmaceuticals & healthcare - Telix Pharmaceuticals: Telix Pharmaceuticals has added significant value by acquiring ANMI, the developer of its TLX591-CDx prostate cancer imaging kit and underlying ‘cold kit’ technology. It also announced plans to accelerate its TLX591 prostate cancer therapeutic into Phase III, based on a third-party review of clinical data that formed part of the Atlab acquisition in September. Following the ANMI acquisition we increase our valuation to A$380m (vs A$303m) or A$1.74 per share (vs A$1.43 per share). FDA agreement to the TLX591 Phase III design would likely prompt a further valuation uplift.
ISIN: AU000000TLX2
Original Article: Telix Pharmaceuticals (TLX) - Prostate programmes boosted